Why Investors Should Love Celgene Corporation (CELG)’s Apremilast

Page 2 of 2

One reason is that apremilast is administered orally rather than via injection as the other drugs are. Another is that the apremilast looks to be quite safer than the other drugs. While Celgene’s drug doesn’t appear to be quite as robust in treating psoriatic arthritis as the biologics, its convenience and safety profile should enable it to gain traction.

Celgene is counting on between $1.5 billion and $2 billion in sales for apremilast by 2017. Considering that Celgene’s current revenue is $5.5 billion, apremilast’s opportunities present plenty of reasons for investors to love this drug.

The article Why Investors Should Love Celgene’s Apremilast originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2